首页> 外文学位 >Mechanisms of vitamin D-mediated growth inhibition in prostate cancer.
【24h】

Mechanisms of vitamin D-mediated growth inhibition in prostate cancer.

机译:维生素D介导的前列腺癌生长抑制机制。

获取原文
获取原文并翻译 | 示例

摘要

1,25-(OH)2 vitamin D3 inhibits cell proliferation of a variety of cancers including prostate. In the human prostate cancer cell line LNCaP, 1,25-(OH)2 vitamin D3-mediated growth inhibition is attributed to cell cycle G1 accumulation which correlates with a robust decrease of cyclin-dependent kinase 2 (CDK2) activity and pronounced relocalization of CDK2 into the cytoplasm. Nuclear targeting CDK2 blocks the 1,25-(OH)2 vitamin D3-mediated growth inhibition and cell cycle G1 accumulation. Further, the nuclear targeted CDK2 blocks 1,25-(OH) 2 vitamin D3-mediated inhibition of CDK2 activity and nuclear exclusion in LNCaP cells. Therefore, CDK2 cytoplasmic relocalization is the key mechanism for 1,25-(OH)2 vitamin D3 effects.;Since cyclin E is important for CDK2 nuclear localization and activation, 1,25-(OH)2 vitamin D3 may exert its effects through regulation of cyclin E. Cyclin E but not a cyclin E mutant deficient in CDK2 binding reverses 1,25-(OH)2 vitamin D3-mediated antiproliferation which suggests the involvement of cyclin E as a mechanism. However, the studies showed no effects of 1,25-(OH)2 vitamin D3 on cyclin E levels, intracellular localization or binding to CDK2.;In order to develop a model for studying 1,25-(OH)2 vitamin D3-mediated antiproliferative effects, LNCaP vitD.R cell line, a vitamin D resistant LNCaP derivative, was generated by continuously culturing of LNCaP cells in medium supplemented with 10 nM 1,25-(OH)2 vitamin D3 for over 9 months. The initial characterization of this cell line showed complete resistance to 1,25-(OH)2 vitamin D3-mediated effects. Analysis of vitamin D regulation of VDR target gene expression revealed that vitamin D resistance in LNCaP vitD.R cells was not due to deregulation of VDR signaling. HDAC inhibitor Trichostatin A (TSA) did not confer sensitivity of LNCaP vitD.R cells to vitamin D treatment suggested the resistance to 1,25(OH) 2 vitamin D3 effect of LNCaP vitD.R cells is not due to histone deacetylase remodeling of the chromatin structure which leads to inhibition of gene transcription. While the partial sensitization of LNCaP vitD.R cells to 1,25(OH)2 vitamin D3 effect by demethylation reagent 5-Aza-2'-deoxycytidine treatment suggested a set of genes involved in 1,25(OH) 2 vitamin D3-mediated antiproliferative effects is silenced via hypermethylation in LNCaP vitD.R cells. These results suggested LNCaP vitD. R cell line is a useful tool and further studies to elucidate the genes involved in this effect will help uncover the mechanisms of 1,25(OH) 2 vitamin D3-mediated antiproliferative effects.
机译:1,25-(OH)2维生素D3抑制多种癌症(包括前列腺癌)的细胞增殖。在人类前列腺癌细胞系LNCaP中,1,25-(OH)2维生素D3介导的生长抑制归因于细胞周期G1积累,这与细胞周期蛋白依赖性激酶2(CDK2)活性的显着下降和HCC的明显重新定位有关。 CDK2进入细胞质。核靶向CDK2阻止1,25-(OH)2维生素D3介导的生长抑制和细胞周期G1积累。此外,核靶向的CDK2阻断LNCaP细胞中1,25-(OH)2维生素D3介导的CDK2活性抑制和核排斥。因此,CDK2的细胞质再定位是1,25-(OH)2维生素D3作用的关键机制。由于细胞周期蛋白E对CDK2的核定位和活化很重要,因此1,25-(OH)2维生素D3可能通过以下途径发挥作用细胞周期蛋白E的调控。细胞周期蛋白E但不是CDK2结合缺陷的细胞周期蛋白E突变体,可以逆转1,25-(OH)2维生素D3介导的抗增殖,这表明细胞周期蛋白E参与其中。然而,研究表明1,25-(OH)2维生素D3对细胞周期蛋白E水平,细胞内定位或与CDK2的结合均无影响。介导的抗增殖作用,通过在补充了10 nM 1,25-(OH)2维生素D3的培养基中连续培养LNCaP细胞9个月以上而产生了LNCaP vitD.R细胞系,一种抗维生素D的LNCaP衍生物。该细胞系的初始表征显示出对1,25-(OH)2维生素D3介导的作用具有完全抗性。维生素D对VDR靶基因表达的调控分析表明,LNCaP vitD.R细胞中的维生素D抗性不是由于VDR信号的失控所致。 HDAC抑制剂曲古他汀A(TSA)不能使LNCaP vitD.R细胞对维生素D敏感,这表明LNCaP vitD.R细胞对1,25(OH)2维生素D3的抗药性不是由于组蛋白去乙酰化酶的重塑。染色质结构导致基因转录的抑制。通过脱甲基化试剂5-Aza-2'-脱氧胞苷处理,LNCaP vitD.R细胞对1,25(OH)2维生素D3部分敏感的结果表明,一组基因涉及1,25(OH)2维生素D3-介导的抗增殖作用通过LNCaP vitD.R细胞中的高甲基化而沉默。这些结果表明LNCaP vitD。 R细胞系是一种有用的工具,进一步研究以阐明参与这种作用的基因将有助于揭示1,25(OH)2维生素D3介导的抗增殖作用的机制。

著录项

  • 作者

    Wang, Zhengying.;

  • 作者单位

    University of Miami.;

  • 授予单位 University of Miami.;
  • 学科 Health Sciences Pharmacology.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 123 p.
  • 总页数 123
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号